Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 4/20 | 0.36 |
| ▸ | TYK2 | P29597 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376407 | 0.95 | KDR (0.41) | BACE1HTTKDRKLK1KLK5 | |
| SCHEMBL5382983 | 0.92 | TERT (0.40) | TERTBACE1HTTKLK1KLK5 | |
| SCHEMBL5384742 | 0.90 | KDR (0.40) | BACE1JAK2JAK1TYK2HTT | |
| SCHEMBL5391846 | 0.89 | SCN9A (0.36) | JAK2JAK1TYK2LMNASMN1; SMN2 | |
| SCHEMBL5390904 | 0.89 | PLG (0.40) | JAK2JAK1TYK2HTTKDR | |
| SCHEMBL5384671 | 0.88 | CRHBP (0.46) | LMNA | |
| SCHEMBL5391415 | 0.88 | SMYD3 (0.43) | BACE1HTTKLK1IDH2LMNA | |
| SCHEMBL5383176 | 0.87 | TERT (0.53) | TERTHTTIDH2LMNASMN1; SMN2 | |
| SCHEMBL5387722 | 0.87 | TERT (0.43) | TERTKLK1KLK5 | |
| SCHEMBL5388912 | 0.87 | SCN9A (0.41) | HTTLMNASMN1; SMN2SCN9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | claimed |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | ANADYS PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005028467-A1 | ANTIBACTERIAL 3,5-DIAMINOPIPERIDINE-SUBSTITUTE AROMATIC AND HETEROAROMATIC COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | claimed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | ANADYS PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005075426-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005028467-A1 | ANTIBACTERIAL 3,5-DIAMINOPIPERIDINE-SUBSTITUTE AROMATIC AND HETEROAROMATIC COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | TERT 2199/4885BACE1 2514/4885JAK2 1863/4885 |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | AMPD3, AAAS, PEPD | TERT 2384/4885BACE1 3134/4885JAK2 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.